Abstracts tagged "COVID-19"

Abstract Number: 0186 • ACR Convergence 2022
Evaluating the Effectiveness & Impact of an In-Person Peer Support Group That Transitioned to a Virtual Platform During the COVID-19 Pandemic
Giselle Rodriguez¹, Priscilla Calvache¹, Lillian Mendez¹, Kimberly Cabrera¹, Roberta Horton¹, Lisa Imundo² and Jillian Rose-Smith¹, ¹Hospital for Special Surgery, New York, NY, ²New York Presbyterian Hospital - Columbia Campus, New York, NY
Background/Purpose: Studies have demonstrated the benefits of online peer support forums in meeting the mental health, disease self-management & coping needs of people living with…
Abstract Number: 0685 • ACR Convergence 2022
The Association of Antiphospholipid Antibodies with Previous SARS-CoV-2 Infection Among Elective Knee Replacement Patients
Lisa Mandl, Medha Barbhaiya, Robyn Lipschultz, Benjamin Swett, Myriam Lin, Agnes Cororaton, Dongmei Sun, Kethy Jules-elysee, Doruk Erkan and Friedrich Boettner, Hospital for Special Surgery, New York, NY
Background/Purpose: Acute SARS-CoV-2 infection has been associated with antiphospholipid antibodies (aPL), though it is unclear if aPL contribute to the hypercoagulability seen with COVID19, or…
Abstract Number: 0762 • ACR Convergence 2022
Rituximab-treated Rheumatic Patients: B-cell Levels Predict Sero-conversion After COVID-19 Boost or Re-vaccination in Initial Vaccine Non-responders
Christian Ammitzboell¹, marianne Kragh thomsen², Jakob Bøgn Andersen¹, Jens Magnus Berth Jensen³, marie-Louise From Hermansen¹, anders Dahl Johannsen¹, Mads Lamm Larsen¹, Clara Elbæl Mistegaard¹, Susan Mikkelsen³, Fruzsina Szabados³, Signe Risbøl Vils¹, Christian Erikstrup³, Ellen-Margrethe Hauge¹ and Anne Troldborg¹, ¹Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ²Department of Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark, ³Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Treatment with rituximab (RTX) has presented a challenge during the COVID-19 pandemic, as antibody response after primary vaccination are markedly reduced and often undetectable.The primary…
Abstract Number: 0790 • ACR Convergence 2022
Sustainability of Immunogenicity of BNT162b2 Vaccine in Patients with Autoimmune Rheumatic Disease, a Retrospective Comparative Study
Omar Alsaed, Masautso Chaponda, Eman Satti, Hadil Ashour, Muna Almaslamani and Samar Al emadi, Hamad Medical Corporation, Doha, Qatar
Background/Purpose: The sustainability of the immunogenicity of BNT162b2 anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in patients with autoimmune rheumatic diseases (ARDs) receiving immunomodulators…
Abstract Number: 0895 • ACR Convergence 2022
COVID-19 Vaccination in Autoimmune Diseases Study: Vaccine Safety in Rheumatoid Arthritis
Naveen R¹, Ioannis Parodis², Mrudula Joshi³, Parikshit Sen⁴, Minchul Kim⁵, Vishwesh Agarwal⁶, Sinan Kardes⁷, James B. Lilleker⁸, Hector Chinoy⁹, Oliver Distler¹⁰, Ai Lyn Tan¹¹, Samuel Shinjo¹², Babur Salim¹³, Tamer A Gheita¹⁴, Nelly Ziade¹⁵, Tsvetelina Velikova¹⁶, Tulika Chatterjee⁵, Arvind Nune¹⁷, Marcin Milchert¹⁸, Abraham Edgar Gracia-Ramos¹⁹, Albert Selva O’Callaghan²⁰, Miguel Angel Saavedra Salinas²¹, Lorenzo Cavagna²², Masataka Kuwana²³, Johannes Knitza²⁴, Jessica Day²⁵, Ashima Makol²⁶, John Pauling²⁷, Chris Wincup²⁸, Erick Zamora Tehozol²⁹, Jorge Rojas Serrano³⁰, Ignacio Garcia-De La Torre³¹, Rohit Aggarwal³², Vikas Agarwal¹, Latika Gupta³³, Elena Nikiphorou³⁴ and CoVAD Study Group³⁵, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Karolinska Institutet, Stockholm, Sweden, ³Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India, ⁴Maulana Azad Medical College, New Delhi, India, ⁵University of Illinois College of Medicine Peoria, Peoria, IL, ⁶Mahatma Gandhi Missions Medical College, Lucknow, India, ⁷Istanbul University, Istanbul, Turkey, ⁸The University of Manchester, Manchester, United Kingdom, ⁹The University of Manchester, Sale, United Kingdom, ¹⁰Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ¹¹University of Leeds, Leeds, United Kingdom, ¹²Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, Brazil, ¹³Fauji foundation hospital Rawalpindi, Rawalpindi, Pakistan, ¹⁴Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, ¹⁵Saint-Joseph University, Beirut, Lebanon, ¹⁶Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ¹⁷Southport and Ormskirk Hospital NHS Trust, Southport, United Kingdom, ¹⁸Pomeranian Medical University in Szczecin, Szczecin, Poland, ¹⁹Instituto Mexicano del Seguro Social, Ciudad de México, Mexico, ²⁰Hospital Universitari Vall d'Hebron, Barcelona, Spain, ²¹IMSS, Ciudad de México, Mexico, ²²Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Pavia, Italy, ²³Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²⁴Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²⁵Walter and Eliza Hall Institute, Melbourne, Australia, ²⁶Mayo Clinic, Rochester, MN, Rochester, MN, ²⁷North Bristol NHS Trust, Bristol, United Kingdom, ²⁸Rayne Institute, University College London, London, United Kingdom, ²⁹Centro Medico Pensiones, Merida, Mexico, ³⁰Hospital Angeles Villahermosa, Ciudad de México, Mexico, ³¹Centro de Est. de Inv. Bas. y Clinica, S.C., Guadalajara, Mexico, ³²Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ³³Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom, ³⁴Leiden University Medical Center & King's College London, London, United Kingdom, ³⁵CoVAD study group, Wolwehampton, United Kingdom
Background/Purpose: COVID-19 vaccination in autoimmune diseases (COVAD) study is a large-scale real-world data on COVID-19 vaccine safety in autoimmune rheumatic diseases (AIRDs) including rheumatoid arthritis…
Abstract Number: 1292 • ACR Convergence 2022
Telemedicine’s Impact on Radiologic Ordering in an Academic Rheumatology Practice During the COVID-19 Pandemic
Ben Kellogg, Robert French, Emily Vinson, Erin McCrum and david leverenz, Duke University School of Medicine, Durham, NC
Background/Purpose: The COVID-19 pandemic necessitated the rapid implementation of telemedicine, and this shift's impact on practice patterns is still being characterized. We theorized that telemedicine…
Abstract Number: 1760 • ACR Convergence 2022
Diagnoses Rates in Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus Patients During COVID-19
W. Cliff Rutter, Will Cavers, Jean Park, Elisea Avalos-Reyes and Kjel Johnson, CVS Health, Lincoln, RI
Background/Purpose: COVID-19 is of particular concern to patients with autoimmune rheumatic diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and systemic lupus erythematosus (SLE).…
Abstract Number: 1932 • ACR Convergence 2022
Efficacy of the COVID-19 Vaccine in Pediatric Systemic Lupus Erythematosus Patients
Yi Shi¹, Catherine Park², Sangeeta Sule² and Sun-Young Ahn², ¹Children's National Hospital, New York, NY, ²Children's National Hospital, Washington, DC
Background/Purpose: The COVID-19 virus has caused significant morbidity and mortality, despite introduction of the COVID vaccine. Immunocompromised patients have been shown to have reduced response…
Abstract Number: 2214 • ACR Convergence 2022
Deep Immune Profiling Uncovers Novel Associations with Variable Clinical Phenotypes of Multisystem Inflammatory Syndrome in Children (MIS-C)
Christopher Redmond¹, Moses Kitakule², Riccardo Castagnoli³, Francesco Licciardi⁴, Cihan Oguz⁵, Maria Cecilia Poli⁶, Aran Son⁵, Sarah Weber⁵, Luigi Notarangelo⁷, Helen Su⁸ and Daniella Schwartz⁹, ¹National Institutes of Health, Rockville, MD, ²Columbia University, New York, NY, ³National Institute of Allergy and Infectious Diseases, Bethesda, MD, ⁴OSPEDALE REGINA MARGHERITA, Torino, Italy, ⁵National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ⁶Roberto del Rio, Santiago, Chile, ⁷NIAID/NIH, Bethesda, MD, ⁸NIH/NIAID, Bethesda, MD, ⁹National Institutes of Health Clinical Center, Bethesda, MD
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a systemic inflammatory condition that follows SARS-CoV2 infection or exposure in children. Clinical presentations are highly variable…
Abstract Number: 0188 • ACR Convergence 2022
COVID-19 and Autoimmune Rheumatic Patients: Behavioral Changes Adopted by Patients in the Midst of the Pandemic
Dzifa Dey¹, Bright Katso², Saudatu Issaka², Derrick Nyame³ and Patrick Adjei¹, ¹University of Ghana Medical School, Accra, Ghana, ²Rheumatology Unit Korle bu Teaching Hospital, Accra, Ghana, ³Korle bu Teaching Hospital, Accra, Ghana
Background/Purpose: Several changes following the COVID-19 pandemic have emerged globally regarding the delivery of healthcare services. Giving concerns that, patients with Autoimmune Rheumatic Disease (AIRD)…
Abstract Number: 0701 • ACR Convergence 2022
Reduced Humoral but Maintained Cellular Immune Response to a 3rd COVID-19 Vaccination in Patients with Immune-Mediated Inflammatory Diseases as Compared to Healthy Controls over a 3-months Observational Period
Daniel Mrak¹, Felix Kartnig¹, Daniela Sieghart¹, Elisabeth Simader¹, Helga Radner¹, Peter mandl², Lisa Göschl¹, Philipp Hofer³, Thomas Hummel¹, Thomas Deimel⁴, Irina Gessl⁴, Renate Kain⁵, Stefan Winkler⁶, Josef Smolen⁴, Thomas Perkmann⁷, Helmuth Haslacher⁷, Daniel Aletaha⁸, Leonhard Heinz¹ and Michael Bonelli¹, ¹Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ²Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Wien, Austria, ³Department of Pathology, Medical University of Vienna, Vienna, Austria, ⁴Medical University of Vienna, Vienna, Austria, ⁵Department of Pathology, Medical University of Vienna, Vienna, ⁶Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria, ⁷Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria, ⁸Medical University Vienna, Wien, Austria
Background/Purpose: A third COVID-19 vaccination is currently recommended for patients under immunosuppression. However, a fast decline of antibodies against the SARS-CoV-2 receptor-binding domain (RBD) of…
Abstract Number: 0765 • ACR Convergence 2022
The Impact of Immunomodulating Treatment on the Immunogenicity of COVID-19 Vaccines in Patients with Immune-mediated Inflammatory Rheumatic Diseases Compared to Healthy Controls. a Swedish Nationwide Study (COVID19-REUMA)
Martina Frodlund¹, Katerina Chatzidionysiou², Anna Södergren³, Eva Klingberg⁴, Anders A Bengtsson⁵, Monika Hansson², Sophie Ohlsson⁶, Elisa Pin⁷, Lars Klareskog⁸ and Meliha Kapetanovic⁹, ¹Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, ²Department of Medicine, Solna, Division of Rheumatology, Karolinska University Hospital at Karolinska Institutet, Stockholm, Sweden, ³Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden and Wallenberg Centre for Molecular Medicine (WCMM), Umeå University, Umeå, Sweden, ⁴Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁵Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, ⁶Department of Clinical Sciences, Lund, Section for Nephrology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, ⁷Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden, ⁸Karolinska Institutet, Stockholm, Sweden, ⁹Lund University, Department for clinical sciences Lund, section of rheumatology and Lund University Hospital Lund and Malmö, Lund, Sweden
Background/Purpose: The aim of the study was to elucidate antibody responses after vaccination with two doses of COVID-19 vaccines in patients with inflammatory rheumatic diseases…
Abstract Number: 0791 • ACR Convergence 2022
Immunogenicity and Safety of a Three-dose SARS-CoV-2 Vaccination Strategy in Patients with Immune-mediated Inflammatory Diseases on Immunosuppressive Therapy
Ingrid Jyssum¹, Anne Therese Tveter¹, Joe Sexton¹, Ingrid Egeland Christensen¹, Siri Mjaaland², David Warren³, Tore K. kvien¹, Kristin Hammersbøen Bjørlykke⁴, Grete Birkeland Kro³, Jørgen Jahnsen⁴, Ludvig A. Munthe³, Espen Haavardsholm¹, Gunnveig Grødeland³, Sella Aarrestad Provan¹, Kristin Kaasen Jørgensen⁴, Guro Goll¹ and Silje Watterdal Syversen¹, ¹Diakonhjemmet Hospital, OSLO, Norway, ²Norwegian Institute of Public Health, Oslo, Norway, ³Oslo University Hospital, Oslo, Norway, ⁴Akershus University Hospital, Oslo, Norway
Background/Purpose: Humoral vaccine responses to SARS-Cov-2 vaccines are impaired and short lasting in patients with immune-mediated inflammatory diseases (IMIDs). Concerns have been raised regarding their…
Abstract Number: 0913 • ACR Convergence 2022
Impact of Disease-modifying Antirheumatic Drugs on Immunogenicity to COVID-19 Vaccine in Patients with Rheumatoid Arthritis
Karam Jabri¹, Linda Burns² and Joseph Grisanti³, ¹University at Buffalo/Catholic Health, Depew, NY, ²Buffalo Rheumatology, Lancaster, NY, ³Buffalo Rheumatology & Medicine, Orchard Park, NY
Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk of infection compared to healthy subjects (1). This is because of a multifactorial complex…
Abstract Number: 1293 • ACR Convergence 2022
Is Virtual Care Here to Stay? : Rheumatology Patients’ Satisfaction in Early vs Late Pandemic
Ummugulsum Gazel¹, Tommy Han², Seyyid Bilal Acikgoz³, Tara Swami¹, Hart goldhar⁴, Urusa Shah³, Rokshana Chowdhury³, Nataliya Milman³, Nancy Maltez¹, Catherine Ivory¹, Susan Humphrey-Murto³ and Sibel Aydin¹, ¹University of Ottawa, Rheumatology, Ottawa, Canada, Ottawa, ON, Canada, ²University of Ottawa, Medical School, Ottawa, Canada, Ottawa, ON, Canada, ³University of Ottawa, Rheumatology, Ottawa, Canada, Ottawa, Canada, ⁴William Osler Health Centre Etobicoke General Site, Rheumatology, Toronto, ON, Canada
Background/Purpose: The COVID-19 pandemic has dramatically changed the delivery of healthcare, with virtual care becoming the new standard. In the early stages of the pandemic,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].